Abstract
Counterfeit pharmaceuticals have been discovered in the parallel supply chain in the UK, which may influence the Commission's consultation on ‘The Future of Pharmaceuticals for Human Use in Europe’ and the Office of Fair Trading's market study into distribution of medicines in the UK.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Intellectual Property Law & Practice
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
